Society for Maternal-Fetal Medicine

The Society for Maternal-Fetal Medicine was established in 1977 and is a not-for-profit organization of over 2,000 members that are dedicated to improving maternal and child outcomes. The organization's headquarters is located in Washington, D.C..

Board certified maternal-fetal medicine physicians have an additional two to three years training in maternal-fetal medicine (MFM) and are involved in the latest advancements in maternal and fetal care. Because of their additional training, MFM's are considered high-risk pregnancy experts. The Society's primary objectives are to promote and expand research and education in maternal-fetal medicine. Congenital heart defects, genetic disorders, preeclampsia, and complications of preterm labor and delivery are a few examples of disorders that maternal-fetal medicine sub-specialists treat.

In 2014 the organization's focus at their annual meeting was discussing ways to reduce maternal morbidity and mortality.[1]

Mission and Vision

Measuring and assessing patient insurance is an important aspect of the patient-care framework. Creating and evaluating treatment efficiency indicators is critical and appropriate for the obstetric population, including physicians and patients alike. To build a measurement method that results in optimum treatment for women and families, thorough deliberation is needed. The mission, vision and strategic plan of SMFM acknowledges that the progress depends on representing the complexity of the populations represented by MFMs.

Mission

The society for maternal-fetal medicine supports the clinical practice of maternal-fetal medicine by providing education, promoting research, and engaging in advocacy to optimize the health of high-risk pregnant women and their babies.

Vision

Optimal pregnancy outcomes for mothers and babies.

Expanded NIPT

The research recommendations from the Society for Maternal-Fetal Medicine and a report in the American Journal of Obstetrics & Gynecology MFM explored methods of minimizing prenatal office visits during COVID-19. The recommendations included extending the usage of non-invasive prenatal testing (NIPT) which can be accessed without a live visit to the office via Natera.[2]

Executive Committee

References
  1. Wickline, Sarah (5 February 2014). "High-Risk Pregnancies Focus of SMFM". medpagetoday.com. Retrieved 10 February 2014.
  2. "Coverage for Natera's Panorama Prenatal Test Extended by Greater Than 20 Million Lives". Cision PR Newswire. 6 April 2020. Retrieved 6 May 2020.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.